Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Oritavancin Doses in Healthy Subjects
NCT02470702Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Jun 2015
- Primary completion
- Oct 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) comparing Oritavancin with Placebo (2 arms). Primary endpoints: Adverse Events and Serious Adverse Events at Day 110, Clinical Safety Laboratory Results at Day 110 and 3 more. Started Jun 2015; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02470702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470702.